Agenda

October 16-19, 2024 | New York City

Register

Wednesday October 16, 2024

  • 9:00 AM – 9:05 AM

    Welcome and Introduction: Leukemia Day

    • Speaker
      • Morton ColemanMD
  • +
    9:05 AM – 10:40 AM

    Session I: AML

    • 9:05 AM – 9:10 AM
      Session Welcome
    • 9:10 AM – 9:30 AM
      Updates in AML Diagnosis and Risk Stratification
    • 9:30 AM – 9:50 AM
      AML Clinical Management: Getting a Newly Diagnosed Patient on the Right Path
    • 9:50 AM – 10:10 AM
      How to make stem cell transplantation for AML better, safer, and more available
    • 10:10 AM – 10:30 AM
      Q&A Session
  • 10:30 AM – 11:00 AM

    Exhibit Hall

  • +
    11:00 AM – 12:45 PM

    Session II: MDS

    • 11:00 AM – 11:05 AM
      Session Welcome
    • 11:05 AM – 11:25 AM
      Lecture: Clinical and Genomic Characterization of Secondary Myeloid Neoplasms.
    • 11:25 AM – 11:45 AM
      Updates in the Treatment of MDS
    • 11:45 AM – 12:05 PM
      Q&A Session
    • 12:05 PM – 12:45 PM
      Case presentation: TP53 MDS
  • 12:45 PM – 2:00 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by AbbVie Medical Affairs)

  • 12:45 PM – 2:00 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by Amgen)

  • 12:45 PM – 2:00 PM

    Lunch Innovation Theater (Non-Accredited)

  • +
    2:00 PM – 3:35 PM

    Session III: MPN

    • 2:00 PM – 2:05 PM
      Session Welcome
    • 2:05 PM – 2:15 PM
      Presentation of Best Leukemia Abstract
    • 2:15 PM – 2:35 PM
      Updates in the management of Polycythemia Vera and Essential Thrombocytopenia
    • 2:35 PM – 2:55 PM
      Initiating and Sequencing Treatments for Myelofibrosis
    • 2:55 PM – 3:15 PM
      Updates in the Management and Monitoring of CML
    • 3:15 PM – 3:35 PM
      Q&A Session
  • 3:35 PM – 4:05 PM

    Exhibit Hall

  • +
    4:05 PM – 5:50 PM

    Session IV: Challenging Topics in Leukemia

    • 4:05 PM – 4:10 PM
      Session Welcome
    • 4:10 PM – 4:30 PM
      Management of CNS Leukemia
    • 4:30 PM – 4:50 PM
      Classification and treatment of Chronic Myelomonocytic Leukemia
    • 4:50 PM – 5:10 PM
      Emerging strategies for Ph+ ALL
    • 5:10 PM – 5:30 PM
      Fertility preservation for myeloid malignancy patients
    • 5:30 PM – 5:50 PM
      Q&A Session
  • 5:50 PM – 7:15 PM

    Welcome Reception

Thursday October 17, 2024

  • 8:00 AM – 8:05 AM

    Welcome and Introduction: Lymphoma Day

    • Speaker
      • John LeonardMD
  • +
    8:05 AM – 9:30 AM

    Session V: Basic Science: What is New and Exciting!

    • 8:05 AM – 8:10 AM
      Session Welcome
    • 8:10 AM – 8:30 AM
      How can we use the immune system to better target lymphoma
    • 8:30 AM – 8:50 AM
      New insights into epigenetics and lymphoma
    • 8:50 AM – 9:10 AM
      Circulating tumor DNA and assessment of risk in lymphoma
    • 9:10 AM – 9:30 AM
      Q&A Session
  • 9:30 AM – 10:00 AM

    Exhibit Hall

  • +
    10:00 AM – 11:55 AM

    Session VI: Approaches in Indolent Lymphomas

    • 10:00 AM – 10:05 AM
      Session Welcome
    • 10:05 AM – 10:25 AM
      How I approach initial therapy of follicular lymphoma
    • 10:25 AM – 10:40 AM
      Debate- How to prioritize therapy for patients with R/R FL- CAR-T
    • 10:40 AM – 10:55 AM
      Debate- How to prioritize therapy for patients with R/R FL- Novel agents including BTKi, EZH2, iMIDS
    • 10:55 AM – 11:10 AM
      Debate- How to prioritize therapy for patients with R/R FL- Bispecifics
    • 11:10 AM – 11:30 AM
      Updates in T cell Lymphoma
    • 11:30 AM – 11:55 AM
      Q&A Session
  • 11:55 AM – 1:10 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by Lilly)

  • 11:55 AM – 1:10 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by Bristol Myers Squibb)

  • 11:55 AM – 1:10 PM

    Lunch Innovation Theater (Non-Accredited)

  • +
    1:10 PM – 3:00 PM

    Session VII: Management of Non-indolent Lymphomas

    • 1:10 PM – 1:15 PM
      Session Welcome
    • 1:15 PM – 1:25 PM
      Presentation of Best Lymphoma Abstract:
    • 1:25 PM – 1:35 PM
      The SASS-ARENA Foundation for Medical Research Award: John Ultmann Award for Major Contributions to Lymphoma Research
    • 1:35 PM – 2:00 PM
      Award Lecture: What does the future hold for management of upfront and relapsed Hodgkin Lymphoma
    • 2:00 PM – 2:20 PM
      Management of Mantle Cell Lymphoma
    • 2:20 PM – 2:40 PM
      What’s New in Marginal Zone Lymphoma
    • 2:40 PM – 3:00 PM
      Q&A Session
  • 3:00 PM – 3:30 PM

    Exhibit Hall

  • +
    3:30 PM – 4:55 PM

    Session VIII: Aggressive Lymphomas

    • 3:30 PM – 3:35 PM
      Session Welcome
    • 3:35 PM – 3:55 PM
      How I approach initial therapy of Aggressive Lymphoma
    • 3:55 PM – 4:15 PM
      How I approach R/R therapy of Aggressive Lymphoma
    • 4:15 PM – 4:35 PM
      Where do CAR-T cells fit in the treatment of aggressive lymphoma?
    • 4:35 PM – 4:55 PM
      Q&A Session
  • +
    4:55 PM – 5:25 PM

    Session IX- Waldenstrom’s Macroglobulinemia

    • 4:55 PM – 5:15 PM
      Lecture: The International Waldenstrom’s Macroglobulinemia Foundation Award:The Bruce Waterfall Memorial Lecture
    • 5:15 PM – 5:25 PM
      Q&A Session
  • 5:25 PM – 5:25 PM

    Adjourn

  • 5:25 PM – 6:40 PM

    Dinner Innovation Theater (Non-Accredited)

  • 6:15 PM – 6:15 PM

    LRF Grand Rounds

Friday October 18, 2024

  • 8:00 AM – 8:05 AM

    Welcome and Introduction: Myeloma Day

  • +
    8:05 AM – 9:30 AM

    Session X: Biology and Pathology for Clinicians

    • 8:05 AM – 8:10 AM
      Session Welcome
    • 8:10 AM – 8:30 AM
      The T cell compartment in MM- therapeutic implications of the bench
    • 8:30 AM – 8:50 AM
      Myeloma and the microenvironment. Comparing marrow and extramedullary disease: future directions
    • 8:50 AM – 9:10 AM
      Precursor disorders (Smoldering Myeloma): if and when to treat. Maintenance intervention or going for the cure
    • 9:10 AM – 9:30 AM
      Q&A Session
  • 9:30 AM – 10:00 AM

    Exhibit Hall

  • +
    10:00 AM – 11:55 AM

    Session XI: Upfront Treatment of Myeloma

    • 10:00 AM – 10:05 AM
      Session Welcome
    • 10:05 AM – 10:25 AM
      Is MRD ready for prime time?
    • 10:25 AM – 10:45 AM
      Optimal upfront treatment: Current and novel immunotherapy approaches
    • 10:45 AM – 11:05 AM
      The High risk elderly frail patient: should CART or bispecifics be incorporated?
    • 11:05 AM – 11:20 AM
      Debate: Management of A Fit Patient: Should CAR-T replace autotransplant as consolidation? Transplant
    • 11:20 AM – 11:35 AM
      Debate: Management of A Fit Patient: Should CAR-T replace autotransplant as consolidation? - CAR-T
    • 11:35 AM – 11:55 AM
      Q&A Session
  • 11:55 AM – 1:10 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by Johnson & Johnson)

  • 11:55 AM – 1:10 PM

    Lunch Innovation Theater (Non-Accredited)

  • 11:55 AM – 1:10 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by Bristol Myers Squibb)

  • 11:55 AM – 1:10 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by Karyopharm)

  • +
    1:10 PM – 3:30 PM

    Session XII: Evolving Options in Multiple Myeloma

    • 1:10 PM – 1:15 PM
      Session Welcome
    • 1:15 PM – 1:25 PM
      Best Myeloma Abstract Presentation
    • 1:25 PM – 1:40 PM
      The SASS Foundation for Medical Research Award: Michaeli Award for Outstanding Contributions to Myeloma
    • 1:40 PM – 2:10 PM
      Award Lecture: The immune microenviroment in myeloma-therapeutic implications
    • 2:10 PM – 2:30 PM
      How to incorporate new therapies in the early relapse patient (1-3 prior lines)
    • 2:30 PM – 2:50 PM
      Beyond BCMA directed CAR-T- therapy- how new targets are being exploited
    • 2:50 PM – 3:10 PM
      T Cell Engagers (Bispecifics) BCMA and other targets.
    • 3:10 PM – 3:30 PM
      Q&A Session
  • 3:30 PM – 4:00 PM

    Exhibit Hall

  • +
    4:00 PM – 6:00 PM

    Session XIII: Treatment in Relapsed/ Refractory Multiple Myeloma

    • 4:00 PM – 4:05 PM
      Session Welcome
    • 4:05 PM – 4:25 PM
      The relapsed refractory patient: when immune approaches are ineffective
    • 4:25 PM – 4:45 PM
      The multiple refractory patient: From Cell Mods to XPO1 inhibitors
    • 4:45 PM – 5:05 PM
      Extramedullary myeloma: Is there any hope? New Treatment approaches
    • 5:05 PM – 5:25 PM
      CAR T-Cell Therapy in Multiple Myeloma: Best Practices in Patient Selection, Treatment, and Multidisciplinary Care
    • 5:15 PM – 5:35 PM
      Q&A Session
    • 5:35 PM – 6:00 PM
      Case Discussions
  • 6:00 PM – 6:00 PM

    Adjourn

  • 6:00 PM – 7:15 PM

    Dinner Innovation Theater (Non-Accredited) (Sponsored by Johnson&Johnson)

Saturday October 19, 2024

  • 8:15 AM – 8:20 AM

    Welcome and Introduction: CLL Day

  • +
    8:20 AM – 9:45 AM

    Session XIV: New and Basic Science

    • 8:20 AM – 8:25 AM
      Session Welcome
    • 8:25 AM – 8:45 AM
      Is Low Count MBL a Precursor to CLL
    • 8:45 AM – 9:05 AM
      CLL: The next Frontier
    • 9:05 AM – 9:25 AM
      Rai Lecture: What is the Cell of Origin for CLL?
    • 9:25 AM – 9:45 AM
      Q&A Session
  • 9:45 AM – 10:15 AM

    Exhibit Hall

  • +
    10:15 AM – 12:20 PM

    Session XV: Treatment Approaches- Sequential and Combinatorial

    • 10:15 AM – 10:20 AM
      Session Welcome
    • 10:20 AM – 10:40 AM
      What To Do with BTK Mutation Data
    • 10:40 AM – 11:00 AM
      Lecture: Sequencing BTKi vs BCL2- Frontline and Relapsed
    • 11:00 AM – 11:20 AM
      Lecture: Combination studies of BTKi and BCl2
    • 11:20 AM – 11:40 AM
      How Should We Be Using MRD Data?
    • 11:40 AM – 12:00 PM
      Management of Richter Transformation
    • 12:00 PM – 12:20 PM
      Q&A Session
  • 12:20 PM – 1:35 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by AstraZeneca)

  • 12:20 PM – 1:35 PM

    Lunch Innovation Theater (Non-Accredited) (Sponsored by AbbVie)

  • 12:20 PM – 1:35 PM

    Lunch Innovation Theater (Non-Accredited)

  • +
    1:35 PM – 3:15 PM

    Session XVI: BTKis and CAR-T in CLL

    • 1:35 PM – 1:40 PM
      Session Welcome
    • 1:40 PM – 2:00 PM
      Lecture: Noncovalent Binding BTK inhibitor - A New Novel Approach/a different binding mechanism
    • 2:00 PM – 2:20 PM
      CAR-T cells in CLL
    • 2:20 PM – 2:30 PM
      Debate- CLL: Debating Therapeutic Strategies
    • 2:30 PM – 2:40 PM
      Debate- CLL: Debating Therapeutic Strategies
    • 2:40 PM – 2:50 PM
      Debate- CLL: Debating Therapeutic Strategies
    • 2:50 PM – 3:00 PM
      Debate- CLL: Debating Therapeutic Strategies
    • 3:00 PM – 3:15 PM
      Q&A Session
  • 3:15 PM – 3:15 PM

    Adjourn